Of these, SLAMF7/CS1, GPRC5D, CD138 and CD38 are showing different clinical success rates, while data for newer tumor antigens like CD70, NKG2DL and κ-light chain are to be expected (11). Here, SLAMF7 is linked to neoplasm.